ID-LF
banner
luizfelipeid.bsky.social
ID-LF
@luizfelipeid.bsky.social
Infectious Diseases 🇧🇷
🌍 🚨 ART Timing & Cryptococcal Meningitis: Starting ART ≤14 days before cryptococcal meningitis diagnosis spikes 2-week mortality to 20.8% vs. 7.1%–13% for longer ART or 12.4% for no ART. 🛑 Pausing ART improves survival.
🔗 Study: doi.org/10.1093/cid/ciae586
#HIV #ART #GlobalHealth #InfectiousDiseases
January 18, 2025 at 7:10 PM
Reposted by ID-LF
New vancomycin guidelines for obese patients recommend AUC-targeted dosing (400–600 mg·h/L) w/ tailored loading and maintenance doses based on weight, renal function, and ICU status to improve safety and efficacy. doi.org/10.1007/s402.... 💊⚖️ #VancomycinDosing #PrecisionMedicine
@idclubr.bsky.social
How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400–600 mg·h/L-Targeted Dosing - Clinical Pharmacokinetics
Background and Objective The latest vancomycin guideline recommends area under the curve (AUC)-targeted dosing and monitoring for efficacy and safety. However, guidelines for AUC-targeted starting dos...
na01.safelinks.protection.outlook.com
January 18, 2025 at 6:46 PM
Reposted by ID-LF
Safety of Triple-Dose Rifampin in Tuberculosis Treatment: A Systematic Review and Meta-Analysis

✅ Just Accepted
⭐ Editor's Choice
#IDSky
Safety of Triple-Dose Rifampin in Tuberculosis Treatment: A Systematic Review and Meta-Analysis
There is growing interest in using high-dose rifampin for tuberculosis treatment. Recent studies suggest that triple-dose rifampin (TDR; ≥30 mg/kg/day) may be unsafe. We updated a systematic review to investigate the safety and efficacy of TDR.
buff.ly
January 17, 2025 at 1:32 AM
Reposted by ID-LF
#Stewardmeme

(Approved 2/2014)
January 17, 2025 at 4:45 AM
Reposted by ID-LF
Impact of policy changes expanding access to direct acting antivirals on hepatitis C virus-related hospitalizations in people with HIV: a population-based study

✅ Just Accepted
#IDSky
Impact of policy changes expanding access to direct acting antivirals on hepatitis C virus-related hospitalizations in people with HIV: a population-based study
The burden of hepatitis C virus (HCV)-related hospitalizations is substantial, particularly among people with HIV and HCV (HIV/HCV). In Ontario, Canada, use of direct-acting antivirals (DAAs) increased following policies removing fibrosis stage restrictions and the approval of pan-genotypic agents in 2017 and 2018, respectively.
buff.ly
January 17, 2025 at 10:11 PM